Cardiac glycosides to treat cystic fibrosis and other il-8 dependent disorders
OwnerBette Pollardinventor
Life of this patent
Estimating the term…
Abstract
A method of inhibiting the secretion of IL-8 and other pro-inflammatory cytokines from cells secreting elevated levels of these compounds is provided. The method includes contacting the cell with a composition comprising a cardiac glycoside such as oleandrin. The cardiac glycoside can be used to treat cystic fibrosis and other IL-8 dependent disorders by lowering levels of spontaneously secreted IL-8 and other pro-inflammatory cytokines. Oleandrin was found to suppress the secretion of IL-8 from cultured CF lung epithelial cells in the nanomolar concentration range. Structure-activity relationships (SARs) for cardiac glycosides are also elucidated.
Claims22
A method of inhibiting or reducing the secretion of IL-8 from a cell secreting elevated levels of IL-8, the method comprising contacting the cell with a composition comprising a cardiac glycoside.
A method of treating disease conditions characterized by elevated levels of IL-8, the method comprising administering to a mammal suffering from the disease a composition comprising an effective amount of a cardiac glycoside.
(canceled)
A method of treating conditions characterized by elevated levels of IL-8 in a human suffering from cystic fibrosis, the method comprising administering to the human an effective amount of a composition comprising a cardiac glycoside.
Dependencies are inferred from the claim text.